Nano Cap New Millennium Growth Fund L P Purchases Shares of 2,750 Bio-Rad Laboratories, Inc. $BIO

Nano Cap New Millennium Growth Fund L P purchased a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) during the fourth quarter, according to its most recent filing with the SEC. The fund purchased 2,750 shares of the medical research company’s stock, valued at approximately $833,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of BIO. Danske Bank A S bought a new stake in Bio-Rad Laboratories in the 4th quarter valued at $30,000. Geneos Wealth Management Inc. increased its holdings in Bio-Rad Laboratories by 115.2% in the 2nd quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 76 shares during the last quarter. Farther Finance Advisors LLC increased its holdings in Bio-Rad Laboratories by 76.9% in the 4th quarter. Farther Finance Advisors LLC now owns 184 shares of the medical research company’s stock valued at $56,000 after acquiring an additional 80 shares during the last quarter. UMB Bank n.a. increased its holdings in Bio-Rad Laboratories by 24.0% in the 3rd quarter. UMB Bank n.a. now owns 207 shares of the medical research company’s stock valued at $58,000 after acquiring an additional 40 shares during the last quarter. Finally, Financial Management Professionals Inc. bought a new stake in Bio-Rad Laboratories in the 4th quarter valued at $61,000. 65.24% of the stock is currently owned by institutional investors.

Bio-Rad Laboratories Stock Performance

Bio-Rad Laboratories stock opened at $287.49 on Friday. The company’s 50-day moving average price is $274.24 and its 200-day moving average price is $292.33. Bio-Rad Laboratories, Inc. has a twelve month low of $211.43 and a twelve month high of $343.12. The company has a quick ratio of 2.37, a current ratio of 3.21 and a debt-to-equity ratio of 0.12. The company has a market cap of $7.69 billion, a PE ratio of 47.36 and a beta of 1.06.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Thursday, April 30th. The medical research company reported $1.89 earnings per share for the quarter, missing analysts’ consensus estimates of $1.97 by ($0.08). Bio-Rad Laboratories had a return on equity of 3.56% and a net margin of 6.52%.The business had revenue of $592.10 million during the quarter, compared to the consensus estimate of $589.91 million. During the same quarter last year, the firm earned $2.54 earnings per share. The business’s quarterly revenue was up 1.1% on a year-over-year basis. On average, equities research analysts forecast that Bio-Rad Laboratories, Inc. will post 10.32 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. Wells Fargo & Company reduced their price target on shares of Bio-Rad Laboratories from $320.00 to $290.00 and set an “equal weight” rating on the stock in a report on Friday, May 1st. Weiss Ratings downgraded shares of Bio-Rad Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a report on Wednesday, May 6th. Royal Bank Of Canada assumed coverage on shares of Bio-Rad Laboratories in a report on Friday, May 15th. They issued an “outperform” rating and a $320.00 price target on the stock. Wall Street Zen downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Finally, Citigroup downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $375.00 to $300.00 in a report on Tuesday, April 7th. One equities research analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $303.33.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.